Noticias y Actividades de Immunocore
Ejecutivos
Ver el organigrama con sus 33 ejecutivos principales
Biografías más buscadas en Immunocore
- Bahija Jallal, Chief Executive Officer and Director
- John Bell, Non Executive Chairman of the Board
- Roy Herbst, Non-Executive Director To The Board
Recientes movimientos de ejecutivos en Immunocore
- William Pao, se ha incorporado a la empresa como Non Executive Director (noticia publicada el 27 de febrero de 2025).
- Travis Coy que ha sido Non-Executive Director, pasa a ser Executive Vice President, Chief Financial Officer and Head of Corporate Development (noticia publicada el 2 de enero de 2025).
- Brian Di Donato, Chief Financial Officer and Head of Strategy, abandonará la empresa el 31 de dic.. de 2024 (noticia publicada el 1 de septiembre de 2024).
Crear su alerta
para seguir los movimientos de los ejecutivos en Immunocore.
Biotecnología
Immunocore tiene 2.347 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Johnson & Johnson Innovative Medicine DIA (Estados Unidos).
Popular M&A news in Biotecnología
- Attovia Therapeutics acaba de anunciar una recaudación de fondos de 90 millones de dólares. (publicado el 21 de abril de 2025).
- Transcarent and Accolade have merged (publicado el 9 de abril de 2025)..
- Kashiv BioSciences acaba de anunciar una recaudación de fondos de 150 millones de dólares. (publicado el 7 de abril de 2025).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Immunocore
- Immunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine :: Immunocore PLC
- Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial :: Immunocore PLC
- Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021 :: Immunocore PLC
- Immunocore to present at upcoming investor conferences :: Immunocore PLC
- Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma :: Immunocore PLC
- Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma :: Immunocore PLC
- Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update :: Immunocore PLC
- Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting :: Immunocore
- Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B :: Immunocore
- Immunocore Reports First Quarter 2021 Financial Results :: Immunocore
- View more press releases Close
Redes sociales sobre Immunocore
- Immunocore en Wikipedia, Google News y Yahoo Finance
- Immunocore en LinkedIn, Twitter y YouTube
